Flagship Biosciences, a Westminster, CO-based provider of computational tissue image analysis technology and services, closed a series A round of funding.
The amount of the deal was not disclosed.
The company intends to use the funds to advance its tissue image analysis software and operational workflow, as well as increase its commercial presence to facilitate drug development partnerships and precision medicine
Led by Trevor D. Johnson, CEO, Flagship Biosciences provides a computational tissue image analysis technology platform and decision support process for tissue biomarkers to apply computational tissue analysis to improve the decision process. It works with pharmaceutical and biotech companies to develop solutions that treat, manage, and cure the world’s most challenging medical conditions.
To date, the company has completed more than 500 projects across the development spectrum, advancing the precision medicine objectives of 6 of the 10 largest pharmaceutical companies. Flagship holds 12 U.S. patents supporting its proprietary digital tissue analysis technology.